H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
21%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Fas and Fas ligand as prognostic factors in human breast carcinoma

Marek Bebenek, Danuta Duś, Joanna Koźlak

Med Sci Monit 2006; 12(11): CR457-461

ID: 462574

Published: 2006-11-01


Background: Several studies on breast cancer patients indicate that Fas/FasL status may have a signifi cant impact on patient survival, but their conclusions are still controversial. The aim of this study was to determine the prognostic value of Fas and Fas ligand (FasL) expressions in the early stages of breast
cancer.
Material/Methods: One hundred and eight patients aged 35–77 years (median: 58), mostly with stage I or II tumors, were analyzed.
Results: Signifi cant associations were noted between Fas expression and lymph node involvement (p

Keywords: Aged, Adult, Antigens, CD95 - biosynthesis, Breast Neoplasms - pathology, Carcinoma - pathology, Fas Ligand Protein - biosynthesis, Female, Gene Expression Regulation, Neoplastic, Humans, Lymphatic Metastasis, Middle Aged, Phenotype, Prognosis, Receptors, Estrogen - metabolism, Time Factors



Back